Vanda Pharmaceuticals | VNDA - Current Liabilities


Vanda Pharmaceuticals reported $145.16M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Akebia Therapeutics USD 160.86M 13.02M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Insmed USD 438.74M 77.74M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Ligand Pharmaceuticals USD 46.74M 6.07M Jun/2026
Merck USD 27.73B 786M Jun/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Moderna USD 2.53B 139M Jun/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 31.93B 1.92B Jun/2026
Takeda JPY 2.76T 335.02B Jun/2026
Teva Pharmaceutical Industries USD 15.65B 2.11B Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Veracyte USD 62.74M 6.62M Jun/2026